Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1976 Dec;26(3):419–424.

Cell-mediated immunity (CMI) to human wart virus and wart-associated tissue antigens.

A K Lee, M Eisinger
PMCID: PMC1540965  PMID: 188577

Abstract

Lymphocyte transformation (LT) and leucocyte migration inhibition in agarose were used to demonstrate cell-mediated immune response to purified human wart virus and wart tissue extract in various subjects with warts and those without past history of warts. Most individuals bearing warts for less than 1 year duration showed positive cell-mediated responses to both the virus and tissue extract whereas very few of those who had warts for longer duration responded to either antigenic preparation. The difference was statistically significant. Subjects who had warts in the past also showed positive responses but these tended to decrease in degree with time. Surprisingly a group of subjects who never had warts before also responded to stimulation with the virus, but not to the extract. The positive response to stimulation with wart tissue extract reflects the presence of wart associated antigens other than the virus. Cell-mediated immunity against the wart virus and wart-associated antigens is probably important in preventing the persistence or even establishment of disease but this protective immunity is short-lived. The lack of quantitative correlation between LT and leucocyte migration inhibition demonstrable in this study suggests that these two are separate events in in vitro lymphocyte stimulation with antigens.

Full text

PDF
419

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Almeida J. D., Goffe A. P. Antibody to wart virus in human sera demonstrated by electron microscopy and precipitin tests. Lancet. 1965 Dec 11;2(7424):1205–1207. doi: 10.1016/s0140-6736(65)90633-1. [DOI] [PubMed] [Google Scholar]
  2. Bloom B. R., Gaffney J., Jimenez L. Dissociation of MIF production and cell proliferation. J Immunol. 1972 Dec;109(6):1395–1398. [PubMed] [Google Scholar]
  3. Cubie H. A. Serological studies in a student population prone to infection with human papilloma virus. J Hyg (Lond) 1972 Dec;70(4):677–690. doi: 10.1017/s0022172400022531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Górski A. J., Dupont B., Hansen J. A., Good R. A. Leukocyte migration inhibitory factor (LMIF) induced by concanavalin A: standardized microassay for production in vitro. Proc Natl Acad Sci U S A. 1975 Aug;72(8):3197–3200. doi: 10.1073/pnas.72.8.3197. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Hellström I., Hellström K. E., Evans C. A., Heppner G. H., Pierce G. E., Yang J. P. Serum-mediated protection of neoplastic cells from inhibition by lymphocytes immune to their tumor-specific antigens. Proc Natl Acad Sci U S A. 1969 Feb;62(2):362–368. doi: 10.1073/pnas.62.2.362. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Matthews R. S., Shirodaria P. V. Study of regressing warts by immunofluorescence. Lancet. 1973 Mar 31;1(7805):689–691. doi: 10.1016/s0140-6736(73)91478-5. [DOI] [PubMed] [Google Scholar]
  7. McDevitt H. O., Benacerraf B. Genetic control of specific immune responses. Adv Immunol. 1969;11:31–74. doi: 10.1016/s0065-2776(08)60477-0. [DOI] [PubMed] [Google Scholar]
  8. Ogilvie M. M. Serological studies with human papova (wart) virus. J Hyg (Lond) 1970 Sep;68(3):479–490. doi: 10.1017/s0022172400042388. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Pass F., Marcus D. M. Wart-associated antigens. I. Isolation of tissue antigens using antibody immunoadsorbents. J Invest Dermatol. 1973 May;60(5):301–306. [PubMed] [Google Scholar]
  10. Pyrhönen S., Johansson E. Regression of warts. An immunological study. Lancet. 1975 Mar 15;1(7907):592–596. doi: 10.1016/s0140-6736(75)91880-2. [DOI] [PubMed] [Google Scholar]
  11. Pyrhönen S., Penttinen K. Wart-virus antibodies and the prognosis of wart disease. Lancet. 1972 Dec 23;2(7791):1330–1332. doi: 10.1016/s0140-6736(72)92776-6. [DOI] [PubMed] [Google Scholar]
  12. Rocklin R. E. Production of migration inhibitory factor by non-dividing lymphocytes. J Immunol. 1973 Mar;110(3):674–678. [PubMed] [Google Scholar]
  13. Senyk G., Hadley W. K. In vitro correlates of delayed hypersensitivity in man: ambiguity of polymorphonuclear neutrophils as indicator cells in leukocyte migration test. Infect Immun. 1973 Sep;8(3):370–380. doi: 10.1128/iai.8.3.370-380.1973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Smithers D. W. Hodgkin's disease. II. Br Med J. 1967 May 6;2(5548):337–341. doi: 10.1136/bmj.2.5548.337. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Spencer E. S., Andersen H. K. Clinically evident, non-terminal infections with herpesviruses and the wart virus in immunosuppressed renal allograft recipients. Br Med J. 1970 Aug 1;3(5717):251–254. doi: 10.1136/bmj.3.5717.251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Tong M. J., Wallace A. M., Peters R. L., Reynolds T. B. Lymphocyte stimulation in hepatitis B infections. N Engl J Med. 1975 Aug 14;293(7):318–322. doi: 10.1056/NEJM197508142930702. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES